PURPOSE: To evaluate the response rates, toxicitiesy, and survival rates, to @entity1206 ( @entity1206 (R)), @entity900 and @entity1260 combination chemotherapy, of the @entity1 with inoperable NSCLC (stage III and IV), who received @entity1206 ( @entity1206 (R)), @entity900 , @entity1260 combinationthe mentioned chemotherapy every 4 weeks. MATERIALS AND METHODS: This study included 26 @entity1 with inoperable NSCLC (stage III and IV), who attended St. Vincent's Hospital Bbetween April 1999 and December 2001, 26 @entity1 were included at St.Vincent's Hospital. The chemotherapy regimen consisted of @entity1206 (25 mg/m2 on days 1 and 8), @entity1260 (1,500 mg/m2 on days 1- and 2 with @entity9614 ), and @entity900 (30 mg/m2 on days 1- to 3). The cycles were administered every 4 weeks. A 25% reduction in the doses reduction was applied into subsequent courses if there werewas grade 3~4 @entity1398 . RESULTS: The median age was 63 (range, 44~73) years and the male : to female ratio was 19 : 7. One @entity1 had stage IIIa, 6 had stage IIIb and 19 had stage IV. Twenty two @entity1 had an ECOG performance status of 0 or 1, andwith 4 hadhave one of 2. Eighteen of the @entity1 had @entity420 , 7 had @entity957 , and 1 had an undifferentiated NSCLC. Two @entity1 were innot able to be evaluatedble due to follow-up loss. Among Of the 24 @entity1 able to be evaluatedble @entity1 , 1 @entity1 had a complete response and 9 @entity1 hada partial responses, and thewith an overall response rate wasof 41.7%. During a total of 104 cycles, grade 3 @entity1398 occurred in 29%, grade 4 @entity1398 in 12%, grade 3~4 @entity882 in 4%, grade 3 @entity417 in 11%, and grade 3~4 @entity33 in 2%. The mean time to progression was 6.4 months (range 1~13) and the median overall survival was 10 months (range 1.5~32). CONCLUSION: The combination of @entity1206 , @entity1260 and @entity900 , in the dose and schedule employed in this study, shows an response rate of 41.7%, but, because grade 3- or 4 @entity1398 occurred in 41%, a careful investigation is needed.

Effect of @entity1206 , XXXX and @entity900 Combination Chemotherapy in Stage III-IV Non-Small-Cell Lung Cancer.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinomas'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity33 :: ('MESH:D052016', 'Disease') :: ['mucositis'] @entity1206 :: ('MESH:C030852', 'Chemical') :: ['vinorelbine', 'Navelbine'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1260 :: ('MESH:D007069', 'Chemical') :: ['ifosfamide'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma'] @entity9614 :: ('MESH:D015080', 'Chemical') :: ['mesna']
@entity1260 :: (MESH:D007069,Chemical) :: ['Ifosfamide']
